BMRN:NSD-Biomarin Pharmaceutical Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 66.68

Change

-3.23 (-4.62)%

Market Cap

USD 13.32B

Volume

2.78M

Analyst Target

USD 111.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing BMRN

BIS ProShares UltraShort Nasd.. 1.91 % 0.95 %

+0.17 (+0.00%)

USD 3.26M
BTEC:SW iShares Nasdaq US Biotech.. 1.63 % 0.00 %

N/A

N/A
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.59 % 0.00 %

+0.37 (+0.00%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.04 (+0.00%)

USD 0.08B
LABS 0.00 % 0.45 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.66 (+0.00%)

N/A
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

+0.19 (+0.00%)

USD 0.07B
EASI 0.00 % 0.75 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.00%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.00%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-2.85 (0.00%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.13 (0.00%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.00%)

N/A
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.41 (+0.00%)

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

+0.56 (+0.00%)

N/A
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

-1.75 (0.00%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.08 (0.00%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

-0.16 (0.00%)

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.12 (0.00%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

+19.60 (+0.00%)

USD 8.17M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.27 (+0.00%)

USD 8.17M
BIOT:SW L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.15 (0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.84% 25% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.84% 25% F 25% F
Trailing 12 Months  
Capital Gain -20.63% 24% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.63% 24% F 26% F
Trailing 5 Years  
Capital Gain -9.44% 45% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.44% 45% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain -0.38% 48% F 39% F
Dividend Return -0.38% 48% F 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.60% 98% N/A 83% B
Risk Adjusted Return -2.59% 46% F 34% F
Market Capitalization 13.32B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.